Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CHM-1101 |
Trade Name | |
Synonyms | CHM 1101|CHM1101 |
Drug Descriptions |
CHM-1101 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing a CD28 costimulatory domain and CD3zeta domain linked to chlorotoxin (CLTX), which targets MMP2 on tumor cells, and potentially induces cytotoxicity (J Clin Oncol 41, 2023 (suppl 16; abstr TPS2086, NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C198977 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CHM-1101 | CHM-1101 | 0 | 1 |